All Posts | Links Medicus - Free Medical News & Perspective

RCT | Leniolisib for Activated phosphoinositide 3-kinase delta syndrome.

22 Nov, 2022 | 13:12h | UTC

Randomized, Placebo-Controlled, Phase 3 Trial of PI3Kδ Inhibitor Leniolisib for Activated PI3Kδ Syndrome – Blood

M-A | Effects of Tai Chi and Qigong on the mobility of stroke survivors.

22 Nov, 2022 | 13:10h | UTC

Effects of Tai Chi and Qigong on the mobility of stroke survivors: A systematic review and meta-analysis of randomized trials – PLOS One

18F-sodium fluoride PET–CT vs. 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer.

22 Nov, 2022 | 13:09h | UTC

Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: 18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis – Cancer Therapy Advisor

M-A | Burden of respiratory syncytial virus infection in older and high-risk adults in developed countries.

22 Nov, 2022 | 13:05h | UTC

Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries – European Respiratory Review

Post-trial follow-up | A brief intervention to prevent alcohol use can have sustained effects among high-risk adolescents.

22 Nov, 2022 | 13:08h | UTC

Effect of Selective Personality-Targeted Alcohol Use Prevention on 7-Year Alcohol-Related Outcomes Among High-risk Adolescents: A Secondary Analysis of a Cluster Randomized Clinical Trial – JAMA Network Open

Commentary on Twitter

RCT: Personality-targeted school-based prevention program “Preventure” can effectively reduce alcohol-related harms up to 7 years later, showing the meaningful & sustained benefits of school-based prevention programs. @theMatilda_USyd https://t.co/HuoZZluc6I #OAResearch

— JAMA Network Open (@JAMANetworkOpen) November 17, 2022

RCT | Zanubrutinib vs. Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

22 Nov, 2022 | 13:03h | UTC

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial – Journal of Clinical Oncology

Pooled analysis of 4 studies | Drug-coated balloons vs. bare metal stents in patients with femoropopliteal arterial disease.

22 Nov, 2022 | 13:02h | UTC

Comparison of Drug-coated Balloons versus Bare Metal Stents in Patients with Femoropopliteal Arterial Disease – Journal of the American College of Cardiology

Commentary: New studies support use of drug-coated balloons over bare metal stents in treating femoropopliteal lesions – University Hospitals Cleveland Medical Center

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given radioisotope therapy for prostate cancer.

22 Nov, 2022 | 12:56h | UTC

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC – Targeted Oncology

RCT | New drug can improve constipation in patients with Parkinson Disease.

22 Nov, 2022 | 13:00h | UTC

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease: A Randomized Controlled Trial – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries:

New Drug Could Ease Parkinson’s-Related Constipation – HealthDay

Oral ENT-01 safe, significantly improves constipation in persons with Parkinson disease – American College of Physicians

Commentary on Twitter

A #RTC of 150 persons with #ParkinsonDisease has found that ENT-01 is safe for up to 25 days of treatment and significantly improves constipation and possibly neurological symptoms: https://t.co/JdDhaHiFOA @MayoClinic pic.twitter.com/IWWCBzvrWV

— Annals of Int Med (@AnnalsofIM) November 8, 2022

RCT | Intermittently scanned continuous glucose monitoring vs. fingerstick testing for Type 1 DM.

21 Nov, 2022 | 14:45h | UTC

RCT | Intermittently scanned continuous glucose monitoring vs. fingerstick testing for Type 1 DM.

Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Continuous Monitoring Outperforms Fingerstick Testing in Patients With T1D, High Glycated Hemoglobin – AJMC

Commentary on Twitter

In persons with type 1 diabetes, intermittently scanned continuous glucose monitoring led to significantly lower glycated hemoglobin levels than participant monitoring with fingerstick testing. https://t.co/2JkNKDyoQJ pic.twitter.com/CXEcARsLD8

— NEJM (@NEJM) October 5, 2022

RCT | The effects of modifying amount and type of dietary carbohydrate on esophageal reflux symptoms.

21 Nov, 2022 | 14:42h | UTC

The Effects of Modifying Amount and Type of Dietary Carbohydrate on Esophageal Acid Exposure Time and Esophageal Reflux Symptoms: A Randomized Controlled Trial – The American Journal of Gastroenterology

Commentary: Study finds that reducing intake of simple sugars improves GERD – Vanderbilt University

RCT | NIV is superior to high-flow nasal cannula to prevent reintubation in patients at high risk for extubation failure.

21 Nov, 2022 | 14:41h | UTC

Effect of postextubation noninvasive ventilation with active humidification vs high-flow nasal cannula on reintubation in patients at very high risk for extubation failure: a randomized trial – Intensive Care Medicine (free for a limited period)

Commentary on Twitter

NIV + active humidification vs HFNC in adult critically ill pts at very high-risk for extubation failure, RCT in 🇪🇸 ICUs: noninvasive ventilation superior to high-flow nasal cannula O2
➡️ reintubation required in 23.3% pts receiving NIV vs 38.8% if HFNC
📎 https://t.co/2mNTf3PYEF pic.twitter.com/Fp2GtZpcLx

— Intensive Care Medicine (@yourICM) November 19, 2022

Cluster RCT | A personalized cooler dialysate provides no benefit for patients receiving maintenance hemodialysis.

21 Nov, 2022 | 14:38h | UTC

Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial – The Lancet (link to abstract – $ for full-text)

Commentary: Clinical trial examines optimal dialysis temperature – University of Western Ontario

Commentary on Twitter (thread – click for more)

Over 2 million people worldwide with #kidneyfailure rely on maintenance #dialysis treatments.

Trial, MyTEMP, assesses the effects of cooler dialysate compared with standard temperature in individuals receiving outpatient maintenance dialysis.🧵 pic.twitter.com/M9JscDqM2v

— The Lancet (@TheLancet) November 17, 2022